FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200370618> ?p ?o ?g. }

• W4200370618 endingPage "2385" @default.
• W4200370618 startingPage "2385" @default.
• W4200370618 abstract "Marine omega-3 fatty acid (omega-3) supplements have been used to treat depression but their ability to prevent depression in the general adult population is unknown.To test effects of omega-3 supplementation on late-life depression risk and mood scores.A total of 18 353 adults participated in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomized trial of cardiovascular disease and cancer prevention among 25 871 US adults. There were 16 657 at risk of incident depression (no previous depression) and 1696 at risk of recurrent depression (previous depression, but not for the past 2 years). Randomization occurred from November 2011 through March 2014; randomized treatment ended on December 31, 2017.Randomized 2 × 2 factorial assignment to vitamin D3 (2000 IU/d), marine omega-3 fatty acids (1 g/d of fish oil, including 465 mg of eicosapentaenoic acid and 375 mg of docosahexaenoic acid) or placebo; 9171 were randomized to omega-3 and 9182 were randomized to matching placebo.Prespecified coprimary outcomes were risk of depression or clinically relevant depressive symptoms (total of incident + recurrent cases); mean difference in mood score (8-item Patient Health Questionnaire [PHQ-8] depression scale).Among 18 353 participants who were randomized (mean age, 67.5 [SD, 7.1] years; 49.2% women), 90.3% completed the trial (93.5% among those alive at the end of the trial); the median treatment duration was 5.3 years. The test for interaction between the omega-3 and the vitamin D agents was not significant (P for interaction = .14). Depression risk was significantly higher comparing omega-3 (651 events, 13.9 per 1000 person-years) with placebo (583 events, 12.3 per 1000 person-years; hazard ratio [HR], 1.13; 95% CI, 1.01-1.26; P = .03). No significant differences were observed comparing omega-3 with placebo groups in longitudinal mood scores: the mean difference in change in PHQ-8 score was 0.03 points (95% CI, -0.01 to 0.07; P = .19). Regarding serious and common adverse events, the respective prevalence values in omega-3 vs placebo groups were major cardiovascular events (2.7% vs 2.9%), all-cause mortality (3.3% vs 3.1%), suicide (0.02% vs 0.01%), gastrointestinal bleeding (2.6% vs 2.7%), easy bruising (24.8% vs 25.1%), and stomach upset or pain (35.2% vs 35.1%).Among adults aged 50 years or older without clinically relevant depressive symptoms at baseline, treatment with omega-3 supplements compared with placebo yielded mixed results, with a small but statistically significant increase in risk of depression or clinically relevant depressive symptoms but no difference in mood scores, over a median follow-up of 5.3 years. These findings do not support the use of omega-3 supplements in adults to prevent depression.ClinicalTrials.gov Identifiers: NCT01696435 and NCT01169259." @default.
• W4200370618 created "2021-12-31" @default.
• W4200370618 creator A5026658319 @default.
• W4200370618 creator A5037910706 @default.
• W4200370618 creator A5045903414 @default.
• W4200370618 creator A5049411008 @default.
• W4200370618 creator A5049822346 @default.
• W4200370618 creator A5053256589 @default.
• W4200370618 creator A5054445689 @default.
• W4200370618 creator A5064264687 @default.
• W4200370618 creator A5078104586 @default.
• W4200370618 creator A5084857746 @default.
• W4200370618 creator A5084949673 @default.
• W4200370618 creator A5086317882 @default.
• W4200370618 creator A5090744975 @default.
• W4200370618 date "2021-12-21" @default.
• W4200370618 modified "2023-10-06" @default.
• W4200370618 title "Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores" @default.
• W4200370618 cites W1979122474 @default.
• W4200370618 cites W2000445173 @default.
• W4200370618 cites W2029191095 @default.
• W4200370618 cites W2038981426 @default.
• W4200370618 cites W2044569835 @default.
• W4200370618 cites W2047790936 @default.
• W4200370618 cites W2048533792 @default.
• W4200370618 cites W2067211004 @default.
• W4200370618 cites W2112935177 @default.
• W4200370618 cites W2129168200 @default.
• W4200370618 cites W2132322340 @default.
• W4200370618 cites W2134404467 @default.
• W4200370618 cites W2135221710 @default.
• W4200370618 cites W2171413723 @default.
• W4200370618 cites W2172132445 @default.
• W4200370618 cites W2403898749 @default.
• W4200370618 cites W2509111386 @default.
• W4200370618 cites W2760711213 @default.
• W4200370618 cites W2790576241 @default.
• W4200370618 cites W2884737999 @default.
• W4200370618 cites W2899572198 @default.
• W4200370618 cites W2899720772 @default.
• W4200370618 cites W2900544757 @default.
• W4200370618 cites W2919675892 @default.
• W4200370618 cites W2971713066 @default.
• W4200370618 cites W2971720535 @default.
• W4200370618 cites W2977466292 @default.
• W4200370618 cites W2998997690 @default.
• W4200370618 cites W3007891836 @default.
• W4200370618 cites W3029959131 @default.
• W4200370618 cites W3047395496 @default.
• W4200370618 cites W4239506499 @default.
• W4200370618 doi "https://doi.org/10.1001/jama.2021.21187" @default.
• W4200370618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34932079" @default.
• W4200370618 hasPublicationYear "2021" @default.
• W4200370618 type Work @default.
• W4200370618 citedByCount "28" @default.
• W4200370618 countsByYear W42003706182022 @default.
• W4200370618 countsByYear W42003706182023 @default.
• W4200370618 crossrefType "journal-article" @default.
• W4200370618 hasAuthorship W4200370618A5026658319 @default.
• W4200370618 hasAuthorship W4200370618A5037910706 @default.
• W4200370618 hasAuthorship W4200370618A5045903414 @default.
• W4200370618 hasAuthorship W4200370618A5049411008 @default.
• W4200370618 hasAuthorship W4200370618A5049822346 @default.
• W4200370618 hasAuthorship W4200370618A5053256589 @default.
• W4200370618 hasAuthorship W4200370618A5054445689 @default.
• W4200370618 hasAuthorship W4200370618A5064264687 @default.
• W4200370618 hasAuthorship W4200370618A5078104586 @default.
• W4200370618 hasAuthorship W4200370618A5084857746 @default.
• W4200370618 hasAuthorship W4200370618A5084949673 @default.
• W4200370618 hasAuthorship W4200370618A5086317882 @default.
• W4200370618 hasAuthorship W4200370618A5090744975 @default.
• W4200370618 hasBestOaLocation W42003706182 @default.
• W4200370618 hasConcept C118552586 @default.
• W4200370618 hasConcept C124490489 @default.
• W4200370618 hasConcept C126322002 @default.
• W4200370618 hasConcept C139719470 @default.
• W4200370618 hasConcept C142724271 @default.
• W4200370618 hasConcept C162324750 @default.
• W4200370618 hasConcept C168563851 @default.
• W4200370618 hasConcept C178790620 @default.
• W4200370618 hasConcept C185592680 @default.
• W4200370618 hasConcept C1862650 @default.
• W4200370618 hasConcept C19038510 @default.
• W4200370618 hasConcept C204787440 @default.
• W4200370618 hasConcept C27081682 @default.
• W4200370618 hasConcept C2776091944 @default.
• W4200370618 hasConcept C2776867660 @default.
• W4200370618 hasConcept C2777171753 @default.
• W4200370618 hasConcept C2780733359 @default.
• W4200370618 hasConcept C2908647359 @default.
• W4200370618 hasConcept C3017514745 @default.
• W4200370618 hasConcept C543025807 @default.
• W4200370618 hasConcept C71924100 @default.
• W4200370618 hasConcept C99454951 @default.
• W4200370618 hasConceptScore W4200370618C118552586 @default.
• W4200370618 hasConceptScore W4200370618C124490489 @default.
• W4200370618 hasConceptScore W4200370618C126322002 @default.
• W4200370618 hasConceptScore W4200370618C139719470 @default.

• next